EUVIMEDEUVIMED entdecken
FallberichtKlinische StudieKohortenstudieOpen Access · CC BY-NC 3.0

Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study

Quincy Chopra, Vincent Peyko iD, Jessica Annie Lee iD, Leo Puhalla, David J Gemmel, Todd Bolotin iD

Open Access Emergency Medicine · 2024-11 · Volume 16 · 267-273

DOI: 10.2147/oaem.s473627 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Open Access Emergency Medicine, 2024-11. Verfasst von Quincy Chopra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Palmdale Regional Medical Center, Palmdale, CA, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cannabinoid Hyperemesis Syndrome (CHS) is characterized by recurrent, paroxysmal episodes of nausea, vomiting, and abdominal discomfort in chronic cannabis users. Optimized CHS treatment data remain limited. Recent prospective evidence have demonstrated haloperidol superiority over ondansetron. Retrospective data suggest the utility of droperidol, a dopamine antagonist like haloperidol, for treating acute CHS.

Objective

To prospectively assess the utility of droperidol plus diphenhydramine to mitigate common CHS symptoms.

Methods

This was a multicenter, prospective interventional study in the emergency department (ED). Participants were administered a study regimen of droperidol and diphenhydramine to treat CHS after enrollment. The primary outcome measure was the change in VAS scores within the droperidol prospective cohort. Symptoms of nausea, vomiting, and abdominal pain were measured using a visual analogue scale (VAS) up to 120 minutes. Secondary measures assessed include repeat visits to the ED within seven days.

Results

Amongst 47 droperidol participants, VAS for nausea and vomiting declined from baseline 8.3±2.0 to 3.1±3.3 at 30 minutes post treatment (p < 0.05), and 1.4±2.4 at 120 minutes (p < 0.05). For abdominal pain, VAS mean was 7.8±2.4 at baseline declining to 3.6±2.9 at 30 minutes (p < 0.05) and 1.7±2.9 at 120 minutes (p < 0.05). Return to the ED within 7 days following droperidol was 12.9% (n=47).

Conclusion

This trial shows significant improvement in symptoms from baseline, 30 and 120 minutes post-treatment and return to the ED within a week post treatment with the study regimen.

Schlagwörter

Stichwörter der Autor:innen

abdominal paincannabinoid hyperemesis syndromedroperidolnauseavomiting

Autor:innen und Institutionen

  • Department of Emergency Medicine, Palmdale Regional Medical Center, Palmdale, CA, USA.
  • Department of Pharmacy, Mercy Health St. Elizabeth Boardman Hospital, Boardman, OH, USA.
  • Northeastern Ohio Medical University, College of Medicine, Rootstown, OH, USA.
  • Department of Research, Mercy Health St Elizabeth Youngstown Hospital, Youngstown, OH, USA.
  • Department of Emergency Medicine, Mercy Health St. Elizabeth Boardman Hospital, Boardman, OH, USA.
  • Lake Erie College of Osteopathic Medicine, College of Medicine, Erie, PA, USA.

ORCID-Profile: Vincent Peyko, Jessica Annie Lee, Todd Bolotin

Zitieren

APA

Chopra, Q., Peyko, V., Lee, J. A., Puhalla, L., Gemmel, D. J., & Bolotin, T. (2024). Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study. Open Access Emergency Medicine, Volume 16, 267-273. https://doi.org/10.2147/oaem.s473627

Vancouver

Chopra Q, Peyko V, Lee JA, Puhalla L, Gemmel DJ, Bolotin T. Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study. Open Access Emergency Medicine. 2024;Volume 16:267-273. doi:10.2147/oaem.s473627

BibTeX
@article{Chopra2024,
  author = {Chopra, Quincy and Peyko, Vincent and Lee, Jessica Annie and Puhalla, Leo and Gemmel, David J and Bolotin, Todd},
  title = {Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study},
  journal = {Open Access Emergency Medicine},
  year = {2024},
  volume = {Volume 16},
  pages = {267--273},
  doi = {10.2147/oaem.s473627}
}
Kostenlos starten →